Avencia Sanchez-Mejias

Avencia Sanchez-Mejias has a diverse work experience in the field of biomedicine and genetics. Avencia is currently the CEO and Co-founder of Integra Therapeutics since November 2020. Prior to that, they worked as a Senior Researcher and Lecturer at Universitat Pompeu Fabra, where they focused on re-engineering biology for modifying the human genome with therapeutic purposes. Avencia also served as a Postdoctoral Research Fellow at the National University of Singapore, conducting research in the same field. Before that, Avencia worked as a Senior Research Associate and Postdoctoral Research Fellow at the University of Miami, Miller School of Medicine, where they specialized in neurodegenerative disorders and the Hedgehog signaling pathway in cancer. Avencia started their career as a PHD Candidate at Instituto de Biomedicina de Sevilla, focusing on the study of congenital genetic disorders.

Avencia Sanchez-Mejias has a strong educational background in the field of science. Avencia began their education at the Universidad de Sevilla in 2001 where they pursued a Bachelor of Applied Science in Biology. After completing their bachelor's degree in 2006, they continued their studies at the same institution and obtained a Master of Science in Biomedical Sciences until 2008. Avencia then pursued a Doctor of Philosophy degree in Molecular Biology from 2006 to 2010 at the Universidad de Sevilla.

In 2017, they enrolled at the University of Cambridge and obtained a Certificate of Proficiency in English (CPE), further enhancing their language skills.